RSI-MRI+ is FDA-cleared imaging software that increases the visibility of restricted water, a hallmark feature of cancerous tissue, to help improve early detection and diagnosis of prostate cancer. Credit: HealthLytix

The US Food and Drug Administration (FDA) has granted 510(k) clearance for HealthLytix’s breakthrough prostate imaging software, RSI-MRI+.

The approval leverages an advanced diffusion MRI technique known as Restriction Spectrum Imaging (RSI). It allows clinicians to detect and diagnose prostate cancer at an early stage.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Claimed to be the first FDA-approved imaging software, RSI-MRI+ uses artificial intelligence (AI) and a tissue microstructure model to enhance the visibility of reduced water in the body’s tissue.

Reduced water is a hallmark feature of several cancerous tissues. The traditional diffusion-weighted imaging applies apparent diffusion coefficient (ADC) to calculate the limited water in the body’s tissue.

Various confounding factors pose a negative influence on ADC’s sensitivity and specificity to cancer, leading to missed or inaccurate diagnosis.

Contrary to the conventional diffusion-weighted imaging (DWI), HealthLytix’s RSI-MRI+ imaging software characterises the restricted signal component, Restricted Signal Map, to provide improved visualisation and quantification of reduced water.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

HealthLytix CEO Nathan White said: “A key innovation of RSI-MRI+ is that it can better characterise the complexity of water diffusion in cancerous tissue, resulting in better performance. With early-stage aggressive cancer, we need more sophisticated approaches to separate what’s important from what’s not important.

“In cancer, that means separating restricted diffusion from other sources of water diffusion that are less relevant.”

Currently, the FDA has cleared RSI-MRI+ only for prostate cancer. In future, the company plans to secure FDA clearance for multiple body regions.

In December, HealthLytix will launch its RSI-MRI+ in the Radiological Society of North America (RSNA) annual meeting in Chicago.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact